Results 281 to 290 of about 122,145 (339)

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of ...
Sadiya S. Khan, C. Ndumele, Dhruv S. Kazi   +2 more
semanticscholar   +3 more sources

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action

Nature Reviews Cardiology, 2023
J. Ussher, D. Drucker
semanticscholar   +3 more sources

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Lancet, The, 2006
D. Drucker, M. Nauck
semanticscholar   +3 more sources

Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials

Obesity Reviews, 2022
Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight loss efficacy were varied.
Junaid Iqbal, Hui-Xuan Wu, Nan Hu, Ying-Hui Zhou, Long Li, Fen Xiao, Ting Wang, Hong-Li Jiang, Shi-Na Xu, Bi-Ling Huang, Houde Zhou   +10 more
semanticscholar   +1 more source

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Expert Opinion on Drug Safety, 2023
Introduction Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide.
R. McIntyre, R. Mansur, J. Rosenblat, A. Kwan   +3 more
semanticscholar   +1 more source

Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials

Obesity Reviews, 2022
Tirzepatide is a new glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) that has shown promising results for weight loss. A Bayesian network meta‐analysis was conducted to compare the efficacy and safety of GLP‐1RAs for obesity management.
Omar S. Alkhezi, A. Alahmed, Osamah M. Alfayez, Osama A. Alzuman, Abdulaali R. Almutairi, O. Almohammed   +5 more
semanticscholar   +1 more source

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists

Incretin hormones are glucoregulatory neurohormones, and GLP-1 and GIP account for about 90% of the incretin effect.1 GLP-1 and GIP are secreted in response to food ingestion and act on the pancreas to stimulate glucose-dependent insulin secretion and blunt inappropriate glucagon secretion ...
Heather P. Whitley, Jennifer M. Trujillo
  +4 more sources

Renal protection with glucagon-like peptide-1 receptor agonists

Current Opinion in Pharmacology, 2020
There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M., Haxhi J., Cirrito T., Pugliese G.   +3 more
openaire   +2 more sources

Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis

Obesity Reviews
Research on Glucagon‐like peptide 1 receptor agonist (GLP‐1RA) has mainly focused on the efficacy of weight loss and not the long‐term efficacy of weight loss maintenance.
Sara Berg, Hannah Stickle, Suzanne J. Rose, Eric C. Nemec   +3 more
semanticscholar   +1 more source